Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
79 studies found for:    "Optic neuritis"
Show Display Options
Rank Status Study
21 Terminated Neuroprotection and Repair in Optic Neuritis
Conditions: Multiple Sclerosis;   Optic Neuritis
Intervention: Drug: Minocycline
22 Active, not recruiting Amiloride Clinical Trial In Optic Neuritis
Conditions: Optic Neuritis;   Multiple Sclerosis
Interventions: Drug: Amiloride;   Drug: Placebo
23 Completed Neuroprotection With Phenytoin in Optic Neuritis
Conditions: Optic Neuritis;   Multiple Sclerosis
Interventions: Drug: Phenytoin;   Drug: Placebo
24 Active, not recruiting Optic Neuritis Treatment Trial (ONTT)
Conditions: Multiple Sclerosis;   Optic Neuritis
Interventions: Drug: Methylprednisolone;   Drug: Prednisone
25 Active, not recruiting Longitudinal Optic Neuritis Study (LONS)
Conditions: Multiple Sclerosis;   Optic Neuritis
Interventions: Drug: Methylprednisolone;   Drug: Prednisone
26 Recruiting Pupillometry Dynamic Measures in Patients Without Ocular or Neurological Disease
Condition: Optic Neuritis
Intervention: Device: pupillary light reflex
27 Recruiting The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset
Condition: Optic Neuritis
Intervention: Biological: blood test of anti-AQP4 antibody
28 Enrolling by invitation Long-Term Assessment of Remyelinating Therapy
Condition: Acute Optic Neuritis
Intervention:
29 Unknown  A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis
Condition: Multiple Sclerosis
Interventions: Drug: ACTHAR Gel (ACTH);   Drug: IV steroids with oral taper
30 Recruiting Optical Coherence Tomography and Optic Neuritis (OCTON)
Condition: Optical Neuritis
Intervention:
31 Suspended Natural History of Optic Neuritis
Condition: Multiple Sclerosis
Intervention:
32 Terminated MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
Condition: Multiple Sclerosis
Interventions: Drug: Verum arm receiving Gilenya®;   Drug: Active Comparator receiving Extavia®
33 Active, not recruiting Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: MD1003 100mg capsule
34 Recruiting Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Optic Neuritis
Intervention: Drug: Mangafodipir (Teslascan)
35 Completed Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
Conditions: Multiple Sclerosis;   Acute Optic Neuritis
Intervention: Drug: BIIB033 (opicinumab)
36 Completed Optical Coherence Tomography in Multiple Sclerosis Patients
Conditions: Multiple Sclerosis;   Optic Neuritis
Intervention:
37 Active, not recruiting Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Ublituximab
38 Recruiting Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve
Condition: Optic; Neuritis, With Demyelination
Interventions: Drug: Amiloride hydrochlorothiazide;   Drug: Sugar pill
39 Recruiting A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder;   Transverse Myelitis;   Optic Neuritis
Intervention:
40 Completed Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Conditions: Multiple Sclerosis;   Optic Neuritis;   Transverse Myelitis;   Acute Brainstem/Cerebellar Syndrome
Intervention: Drug: interferon beta 1a 30 ug IM once weekly

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.